Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112901 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Yuxin Jiang und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Southeast University, Nanjing 210000, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma, Immunotherapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 95 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: A minority of patients with extensive-stage small cell lung cancer (ES-SCLC) exhibit prolonged survival following first-line chemoimmunotherapy, which warrants the use of reliable biomarkers. Here, we investigated the disparities in genomics and immune cell spatial distribution between long- and short-term survival of patients with ES-SCLC. METHODS: We retrospectively recruited 11 long-term (>2 years) and 13 short-term ( 3.1) were associated with favorable survival. At the single-gene and pathway levels, tNGS revealed that MCL1 and STMN1 amplification and alterations in the apoptosis pathway were more common in short-term survivors, whereas alterations in the DLL3, KMT2B, HGF, EPHA3, ADGRB3, lysine deprivation, and HGF-cMET pathways were observed more frequently in long-term survivors. mIHC analysis of immune cells with different spatial distributions revealed that long-term survivors presented increased numbers of M1-like macrophages in all locations and decreased numbers of CD8+ T cells in the tumor stroma. Bulk transcriptomic analysis demonstrated that high levels of STMN1 and DLL3 represented an immune-suppressive tumor immune microenvironment (TIME), whereas HGF indicated an immune-responsive TIME. The expression levels of our putative genes were comparative in both TP53/RB1 mutant-type and TP53/RB1 wild-type. At the single-cell level, STMN1, MCL1, and DLL3 were highly expressed among all molecular subtypes (SCLC-A, SCLC-N, and SCLC-P), with STMN1 being enriched in cell division and G2M checkpoint pathways. CONCLUSIONS: For ES-SCLC patients receiving first-line chemoimmunotherapy, alterations in DLL3, KMT2B, HGF, EPHA3, and ADGRB3 and a greater proportion of M1-like macrophages infiltration in all locations were predictors of favorable survival, while MCL1 and STMN1 amplification, as well as a greater proportion of CD8+ T cells infiltrating the tumor stroma, predicted worse survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Southeast University, Nanjing 210000, China.
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China.
- Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Nanjing Medical School, Nanjing 210002, China.
- Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, China.
- School of Medicine, Southeast University, Nanjing 210000, China; Department of Respiratory and Critical Care Medicine, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China;…
Zitieren
APA
Jiang, Y., Xie, J., Cheng, Q., Cai, Z., Xu, K., Lu, W., Wang, F., Wu, X., Song, Y., Lv, T., & Zhan, P. (2024). Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112901
Vancouver
Jiang Y, Xie J, Cheng Q, Cai Z, Xu K, Lu W, et al. Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112901
BibTeX
@article{Jiang2024,
author = {Jiang, Yuxin and Xie, Jingyuan and Cheng, Qinpei and Cai, Zijing and Xu, Ke and Lu, Wanjun and Wang, Fufeng and Wu, Xiaoying and Song, Yong and Lv, Tangfeng and Zhan, Ping},
title = {Comprehensive genomic and spatial immune infiltration analysis of survival outliers in extensive-stage small cell lung cancer receiving first-line chemoimmunotherapy},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112901}
}
EUVIMED